Immuno-Oncology Market
Published date: Oct 2025
add_shopping_cartBuy Now
get_appDownload Sample
Immuno-Oncology Market
Published date: Oct 2025 •
Formats:
Table of Contents
- Report Overview
- Key Takeaways
- Therapy Analysis
- Indication Analysis
- Stage / Line of Therapy Analysis
- Distribution Channel Analysis
- Key Market Segments
- Drivers
- Restraints
- Opportunities
- Impact of Macroeconomic / Geopolitical Factors
- Latest Trends
- Regional Analysis
- Key Players Analysis
- Recent Developments
- Report Scope
Immuno-Oncology Market By Therapy, (Immune Checkpoint Inhibitors, Monoclonal Antibodies (mAbs), Cell & Gene Therapies, Cancer Vaccines, Oncolytic Virus Therapy, Combination Therapies), By Indication (Solid Tumours, Hematologic Malignancies), By Stage/ Line of Therapy (First-line (frontline), Second-line, Third-line/later lines, Adjuvant (post-surgery), Neoadjuvant (pre-surgery)), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
-
keyboard_arrow_up
-
-
- Merck & Co.
- Bristol-Myers Squibb (BMS)
- Roche Holding AG
- AstraZeneca
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Sanofi S.A.
- Gilead Sciences (Kite Pharma)
- Eli Lilly and Company
- Takeda Pharmaceutical Company
- GlaxoSmithKline (GSK)
- Incyte Corporation
- Johnson & Johnson
- Bayer AG
- Genmab A/S
- Regeneron Pharmaceuticals
- BeiGene Ltd.
- Other key players
- 143626
- Oct 2025
Trusted by more than 17382 organizations globally
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
✖
Request a Sample Report
We'll get back to you as quickly as possible
